Quantitative Analysis of the Enhanced Permeation and Retention (EPR) Effect

Andrew D. Wong\textsuperscript{1,2*}, Mao Ye\textsuperscript{3*}, Martin B. Ulmschneider\textsuperscript{1,2}, Peter C. Searson\textsuperscript{1,2,3*}

\textsuperscript{1} Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland, United States of America, \textsuperscript{2} Institute for Nanobiotechnology (INBT), Johns Hopkins University, Baltimore, Maryland, United States of America, \textsuperscript{3} Department of Physics and Astronomy, Johns Hopkins University, Baltimore, Maryland, United States of America

☯ These authors contributed equally to this work.
* searson@jhu.edu

Abstract

Tumor vasculature is characterized by a variety of abnormalities including irregular architecture, poor lymphatic drainage, and the upregulation of factors that increase the paracellular permeability. The increased permeability is important in mediating the uptake of an intravenously administered drug in a solid tumor and is known as the enhanced permeation and retention (EPR) effect. Studies in animal models have demonstrated a cut-off size of 500 nm - 1 \( \mu \)m for molecules or nanoparticles to extravasate into a tumor, however, surprisingly little is known about the kinetics of the EPR effect. Here we present a pharmacokinetic model to quantitatively assess the influence of the EPR effect on the uptake of a drug into a solid tumor. We use pharmacokinetic data for Doxil and doxorubicin from human clinical trials to illustrate how the EPR effect influences tumor uptake. This model provides a quantitative framework to guide preclinical trials of new chemotherapies and ultimately to develop design rules that can increase targeting efficiency and decrease unwanted side effects in normal tissue.

Introduction

In a growing solid tumor, the combination of hypoxic environment and inflammatory response leads to the up-regulation of angiogenic factors and down-regulation of angiogenic inhibitors, promoting the formation of new vessels. This process involves local removal of smooth muscle cells and degradation of basement membrane and extracellular matrix (ECM) by matrix metalloproteinases (MMPs). At the same time, the proliferation of tumor cells causes expansion of the microenvironment and generates local compressive forces [1]. Expansion increases the average spacing between vessels, reducing the supply of nutrients, and creating hypoxic regions in the tumor. The compressive forces generated by tumor growth leads to contraction of blood vessels that contributes to increased resistance to flow. Compressive forces on lymphatic vessels lead to poor lymphatic drainage and increased interstitial fluid pressure.
This combination of biochemical and mechanical factors leads to an irregular vascular architecture, increased resistance to blood flow, poor perfusion, and increased permeability. The leakiness of the tumor vasculature is key for systemic delivery of anticancer drugs to a solid tumor, and is known as the Enhanced Permeation and Retention (EPR) effect (Fig 1A) [2, 3]. In animal models, the cut-off size for extravasation from the tumor vasculature varies from 200 nm to 1.2 μm depending on the tumor type [4–6]. A diameter of about 200 nm is often considered an upper limit for successful drug delivery [7, 8].

Despite its critical importance in cancer therapy, surprisingly little is known about the kinetics of the EPR effect. Here we present a model for the pharmacokinetics of a chemotherapeutic drug or nanomedicine that takes into account extravasation from circulation at the tumor site by the EPR effect and intravasation back into circulation. We use data from clinical trials of Doxil and doxorubicin to quantitatively assess the influence of the EPR effect on tumor uptake.

**Model**

Accumulation of a drug or nanomedicine in a solid tumor by the EPR effect is dependent on the concentration in blood, and hence requires knowledge of the pharmacokinetics. To evaluate drug accumulation in a solid tumor, we begin with a two compartment model with a central compartment representing the vascular system and highly perfused organs, and a peripheral compartment representing uptake in normal tissue (Fig 1B) [9]. In conventional models, extravasation of a drug at the tumor site is implicitly combined with clearance by the kidneys, mononuclear phagocyte system (MPS), and any other mechanisms, into the rate constant $k_{10}$. To distinguish tumor accumulation by the EPR effect from other elimination pathways, we introduce a tumor “compartment” to the model and define rate constants specifying drug accumulation and removal from the tumor. Drug extravasation into the tumor by the EPR effect is described by the rate constant $k_{epr}$, and intravasation from the tumor back into circulation is described by $k_{b}$. We define the rate constant $k_{d}$ to describe elimination by the kidneys, MPS, and any mechanisms other than tumor uptake. For the case when $k_{b} = 0$, then $k_{10} = k_{epr} + k_{d}$ (see Text A in S1 File for details). As we show below, the rate of tumor uptake is expected to be slower than the rate of elimination under most clinical conditions and hence $k_{10} \ll k_{d}$.

In classic pharmacokinetic models, the time dependence of the measured drug concentration in blood or plasma (mg mL$^{-1}$) is fit to a model with first order rate constants describing exchange with the peripheral compartment ($k_{12}$ and $k_{21}$) and elimination ($k_{10}$) (Fig 1C) [9]. A problem in using concentration to describe the amount of drug is that a volume must also be defined. While this is straightforward for the vascular system, it is not well defined for the peripheral tissue or a tumor. To avoid this problem, we define the amount of drug in the different compartments: where $N_{bl}$, $N_{p}$, and $N_{t}$ represent the amount (in mg) of drug in blood, peripheral tissue, and tumor tissue, respectively. To account for the exchange of drug into and out of the peripheral compartment ($N_{p}$), we define $k_{p}$ and $k_{d}$, respectively.

The rate equations can be written in terms of first order rate constants:

$$\frac{dN_{bl}}{dt} = -(k_{d} + k_{epr} + k_{p})N_{bl} + k_{d}N_{p} + k_{p}N_{t}$$

$$\frac{dN_{p}}{dt} = k_{p}N_{bl} - k_{d}N_{p}$$

$$\frac{dN_{t}}{dt} = k_{epr}N_{bl} - k_{d}N_{t}$$

Quantitative Analysis of the EPR Effect
Note that this is a dissipated system where mass balance does not hold for these three compartments:

\[ \frac{dN_{bl}}{dt} + \frac{dN_{p}}{dt} + \frac{dN_{t}}{dt} = -k_{el}N_{bl} \]  

To evaluate the influence of the rate constant for tumor uptake by the EPR effect on tumor accumulation, we consider the pharmacokinetics for Doxil and doxorubicin. Pharmacokinetic data are often empirically fit to an equation consistent with a two compartment model (Text B in S1 File) of the form:

\[ N_{bl} = Ae^{-\alpha t} + Be^{-\beta t} \]

where A, B, \( \alpha \), and \( \beta \) are constants. To obtain the rate constants \( k_{12} \), \( k_{21} \), and \( k_{10} \) for Doxil and doxorubicin, we use pharmacokinetic parameters (A, B, \( \alpha \), and \( \beta \)), from a clinical trial (Table 1). The pharmacokinetics are analyzed in terms of the amount of the drug in circulation \( N_{bl} \) in units of mg. The rate constants \( k_{12} \), \( k_{21} \), and \( k_{10} \) are related to the parameters A, B, \( \alpha \), and \( \beta \).
and $\beta$ by the following equations (see Text D in S1 File for derivation):

$$k_{21} = \frac{\beta A + \alpha B}{A + B}$$ \hspace{1cm} (6)

$$k_{10} = \frac{\alpha \beta}{k_{21}}$$ \hspace{1cm} (7)

$$k_{12} = \alpha + \beta - k_{21} - k_{10}$$ \hspace{1cm} (8)

Recognizing that $k_p = k_{12}$, $k_d = k_{21}$, and taking $k_{10} = k_{01}$, the rate equations (Eqs. 1–4) were solved numerically using Matlab (see Text A in S2 File for code) to evaluate the influence of $k_{\text{epr}}$ and $k_{d}$ on tumor accumulation.

### Results

**Doxil**

Doxil is a liposomal formulation of doxorubicin and was FDA-approved for AIDS-related Kaposi’s sarcoma in 1995, for ovarian cancer in 1999, and for multiple myeloma in 2007 [10]. In 2013, the use of the generic version Lipodox was approved for treatment of ovarian cancer and Kaposi’s sarcoma. Doxil is formulated from a combination of fully hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and a lipid with a polyethylene glycol (PEG) head group (DSPE-PEG2k) [11]. The PEG groups inhibit protein adhesion and slow the rate of uptake by the MPS. Doxil liposomes are about 100 nm in diameter and contain about 10,000–15,000 doxorubicin molecules [11].

The pharmacokinetics of Doxil are characterized by a large area under the curve (AUC), slow clearance rate (CL), small distribution volume ($V_d$), and long elimination half time ($t_{1/2}$) [10, 12, 13]. The distribution volume is close to the blood volume and hence the pharmacokinetics for Doxil are sometimes analyzed using a single compartment model. The pegylated lipids in the liposomes result in a long circulation half-time, typically 3–4 days [13].

Pharmacokinetic data were taken from a clinical trial where cancer patients were administered either 25 mg m$^{-2}$ or 50 mg m$^{-2}$ of Doxil, or free doxorubicin [12]. We consider the data

|                   | Doxil     | Doxorubicin |
|-------------------|-----------|-------------|
| $A$ (mg)          | 34.5      | 28.5        |
| $B$ (mg)          | 61.0      | 1.1         |
| $\alpha$ (h$^{-1}$)| 0.301     | 11.6        |
| $\beta$ (h$^{-1}$)| 0.015     | 0.067       |
| $k_{12}$, $k_p$ (h$^{-1}$) | 0.0956 | 9.57 |
| $k_{21}$, $k_d$ (h$^{-1}$) | 0.198 | 0.494 |
| $k_{10}$ (h$^{-1}$) | 0.0228 | 1.56 |

The parameters $A$, $B$, $\alpha$, and $\beta$ were reported by Gabizon et al. from a clinical trial from a fit to the amount of drug in circulation at time t after administration using a dual exponential decay model: $N_{bl}(t) = Ae^{-\alpha t} + Be^{-\beta t}$, where $t$ is the time and $\alpha$ and $\beta$ are decay constants. $A$ and $B$ are reported in units of mg, using a blood volume of 5 L. The rate constants $k_{12} (= k_p)$, $k_{21} (= k_d)$, and $k_{10}$ are obtained from the parameters $A$, $B$, $\alpha$, and $\beta$ by assuming a two-compartment model (see Text B in S1 File for details).

doi:10.1371/journal.pone.0123461.t001
from the 50 mg m\(^{-2}\) cohort (N = 14 for Doxil and N = 4 for doxorubicin). Gabizon et al. [12] used a two compartment model (Fig 1C) to describe the pharmacokinetic data, and reported the values of A, B, \(\alpha\), and \(\beta\) that best fit the measured blood concentration versus time curves using a biexponential function (Table 1). To convert the dose (which has units of mg m\(^{-2}\)) and pharmacokinetic constants A and B (which have units of mg L\(^{-1}\)) to amounts, we use a body surface area of 1.8 m\(^2\) and a blood volume of 5 L [14].

Values for the rate constants \(k_{12}\), \(k_{21}\), and \(k_{el}\) for Doxil were obtained from the values for A, B, \(\alpha\), and \(\beta\) (Table 1) from the clinical trial using a standard two compartment model (Fig 1C) [12]. In our model, the amount of drug is specified for each compartment instead of concentration (Fig 1D). We take \(k_p = k_{12}\), \(k_d = k_{21}\), and \(k_{el} = k_{10}\) and apply these rate constants to our three compartment model while initially assuming a negligible rate of extravasation from the EPR effect (\(k_{epr} \approx 0\) (Fig 1E). As anticipated, the numerical solution of the rate equations shows excellent agreement with the pharmacokinetic data (Fig 2A), since we are simulating a two compartment model when \(k_{epr} = 0\). Next, we introduce the tumor compartment and increase values of \(k_{epr}\) while keeping \(k_p\), \(k_d\), and \(k_{el}\) fixed, to determine detectable changes in the pharmacokinetics due to the EPR effect.

We calculate the pharmacokinetics for Doxil using the values for \(k_p\), \(k_d\), and \(k_{el}\) obtained from Gabizon et al. (Table 1) and different ratios of \(k_{epr}/k_{el}\) (\(10^{-1}\), \(10^{-2}\), \(10^{-3}\), and 0) with \(k_e\) fixed at 0 (Fig 2B). By exploring a range of ratios of \(k_{epr}/k_{el}\) we can simulate the EPR effect for
a variety of tumors with varying degrees of drug absorption relative to other elimination pathways. When the rate constant for tumor uptake by the EPR effect is smaller than the rate constant for elimination (\(k_{\text{epr}}/k_{\text{d}} < 0.1\)), the influence of the EPR effect is not seen in the pharmacokinetics. Therefore, as long as \(k_{\text{d}} >> k_{\text{epr}}\), the pharmacokinetics for subjects with and without tumors would be indistinguishable (Fig 2B). As we show below, \(k_{\text{epr}}\) is expected to be much slower than \(k_{\text{d}}\) for most cases of clinical interest.

From the numerical simulations we can extract the amount of Doxil accumulated in the tumor (\(N_{\text{t}}\)) for the different values of \(k_{\text{epr}}\) (Fig 2C). For \(k_{\text{epr}}/k_{\text{d}} = 10^{-1}\), tumor uptake by the EPR effect increases quickly in the first few hours and then asymptotically approaches a maximum corresponding to about 10% of the initial dose after 4 days. Decreasing the value of \(k_{\text{epr}}/k_{\text{d}}\) results in slower accumulation and a maximum that decreases by an order of magnitude for every order of magnitude decrease in \(k_{\text{epr}}/k_{\text{d}}\).

In xenograft mouse models, the maximum reported accumulation of nanomedicines is around 10% of the initial dose [15]. However, tumor xenografts are usually formed from cell lines that result in highly vascularized and leaky tumors, and hence the fraction of the initial dose accumulated in the tumor and \(k_{\text{epr}}\) is expected to be much higher than in a human subject. Even when using overestimated values of \(k_{\text{epr}}\) to achieve 10% ID accumulated in tumors (e.g. \(k_{\text{epr}}/k_{\text{d}} = 10^{-1}\), there is only a negligible change in the pharmacokinetics compared to when \(k_{\text{epr}} = 0\) (Fig 2B-2C). This result implies that tumor accumulation by the EPR effect is not a significant sink for the drug in circulation, i.e \(k_{\text{d}}N_{\text{d}} >> k_{\text{epr}}N_{\text{t}}\).

So far we have assumed that there is no intravasation back into circulation (\(k_{\text{b}} = 0\)), corresponding to the case where all extravasated drug remains in the tumor. This could occur by rapid uptake and sequestration of the drug by tumor cells close to the vessels or by active targeting resulting in irreversible binding to tumor cells. We next fix \(k_{\text{epr}}/k_{\text{d}} = 10^{-3}\), and assess how \(k_{\text{b}}\) influences drug accumulation at the tumor site.

When \(k_{\text{b}} \approx k_{\text{epr}}\) there is relatively little difference in tumor accumulation (Fig 2D). However, for larger values of \(k_{\text{b}}\) (\(k_{\text{b}}/k_{\text{epr}} > 10\)), the amount of drug in the tumor reaches a maximum and then decreases at longer times. With increasing \(k_{\text{b}}\), the maximum occurs at shorter times and the rate of intravasation from the tumor increases. This effect is due to the fact that initially the amount of drug in the tumor is small, and hence the rate of transport from the tumor back to the vascular system (\(k_{\text{b}}N_{\text{t}}\)) is also small. At longer times the amount of drug in circulation decreases resulting in a decrease in the rate of extravasation to the tumor, and the amount of drug in the tumor increases, resulting in an increase in the rate of intravasation. Eventually, the rate of intravasation becomes larger than the rate of extravasation. A similar maximum in tumor accumulation has been reported for administration of a pegylated liposome in a mouse model [16]. These simulations highlight an important insight that is often neglected: the EPR effect allows transport in both directions—into and out of the tumor.

The model presented here provides a framework to assess the influence of the EPR effect on tumor uptake. The rate of uptake is described by \(k_{\text{epr}}N_{\text{d}}\) highlighting the fact that the rate constant represents extravasation of the drug along the total length of the tumor vasculature. Since it is difficult to measure the length of tumor vasculature, normalization by the tumor size may be a reasonable alternative. Since the rate constant for tumor uptake represents the leakiness of the tumor vasculature, it is expected to be dependent on the tumor type and is likely to vary from patient to patient. This is discussed in more detail below.

The rate of intravasation from the tumor back to the vasculature is described by \(k_{\text{b}}N_{\text{t}}\). For a drug molecule in circulation under pulsatile flow, the residence time of a drug molecule in the vicinity of a defect in the endothelium of the tumor vasculature is expected to be relatively short, and hence the probability of extravasation is expected to be low. Conversely, the residence time for a drug molecule in the vicinity of a defect on the tumor side of the endothelium...
is expected to be much higher since the rate of interstitial flow is much lower than blood flow. Consequently, the probability of extravasation is expected to be lower than the probability of intravasation (i.e. $k_b > k_{epr}$). While other processes such as diffusive transport and cellular uptake are not explicitly determined in this model (Fig 1), their effects on the rate of intravasation are included in $k_b$. For example, in tumors where diffusive transport is fast or where active targeting limits intravasation, the rate of intravasation ($k_b N_t$) is expected to be much smaller than the rate of extravasation ($k_{epr} N_{bl}$).

In this model we make no assumptions about the fate of the drug after extravasation. Diffusive transport into the tumor, non-specific binding or targeting to cell membranes, cellular uptake, and metabolism will all influence the amount of free drug in the tumor close to the vasculature that is available for intravasation back into circulation. With experimental progress in quantitative assessment of the EPR effect, future models can incorporate these downstream processes.

**Doxorubicin**

To provide a comparison to tumor accumulation for Doxil, we also assess the influence of the EPR effect on tumor accumulation of doxorubicin. Doxorubicin is an anthracyline commonly used in the treatment of a wide range of cancers. The distribution volume for free doxorubicin is very large illustrating that a significant amount of the drug is taken up in normal tissues [17–20]. The AUC for doxorubicin is about three orders of magnitude smaller than Doxil resulting in a clearance rate about three orders of magnitude larger [17–20]. The elimination half-time for doxorubicin is about 20–25 h.

Pharmacokinetic data for doxorubicin were obtained from Gabizon et al. (Fig 3A) [12]. Similar values have been reported in other clinical trials [17–19]. Values for the pharmacokinetic parameters $A$, $B$, $\alpha$, and $\beta$, as well as the rate constants $k_{12}$, $k_{21}$, and $k_{10}$, are provided in Table 1.

As described previously for Doxil, tumor uptake of doxorubicin by the EPR effect is not expected to be seen in the pharmacokinetics due to the dominant contribution of non-tumor elimination pathways (Fig 3B). First we consider tumor accumulation for different values of $k_{epr}/k_{el}$ with $k_b = 0$ (Fig 3C). The increase in tumor accumulation is rapid during the initial distribution phase. However, as the amount in blood decreases rapidly in the first few minutes, tumor accumulation slows significantly during the elimination phase. The maximum amount of drug accumulated in the tumor is lower than for Doxil due to the lower concentration in blood at all times and the faster clearance ($k_{el}$) (see Table 1). Decreasing the value of $k_{epr}/k_{el}$ results in significantly lower accumulation in the tumor.

Fixing $k_{epr}/k_{el} = 10^{-3}$, we assess the influence of intravasation ($k_b$) on tumor accumulation (Fig 3D). For $k_b/k_{epr} \geq 10$, tumor accumulation reaches a maximum and subsequently decreases. The rate of decrease is much faster than for Doxil, especially for larger values of $k_b/k_{epr}$ as the amount of drug in circulation decreases rapidly in the distribution phase.

**Drug delivery and distribution within the tumor microenvironment**

In Figs 2 and 3 we show the global accumulation of anticancer drugs within a tumor for an initial dose of 100 mg. To illustrate drug accumulation in the local tumor microenvironment, we consider a 100 $\mu$m length of tumor vessel. Assuming a tumor volume of 1 cm$^3$ and vessel length density of 150 mm mm$^{-3}$, the total length of tumor vasculature is about 150 m with an average vessel diameter of 30 $\mu$m (S1 Table) [21]. A 100 $\mu$m segment of a 30 $\mu$m diameter vessel has about 3–4 endothelial cells around the circumference and is about 3–4 cell lengths long.

Taking $k_{epr}/k_{el} = 10^{-3}$ (0.1% ID with $k_b = 0$), the local accumulation of Doxil along a 100 $\mu$m segment corresponds to $10^4$ to $10^6$ liposomes, depending on the value of $k_b$. For doxorubicin,
the total accumulation along a 100 μm vessel segment is $10^7 \text{–} 10^{10}$ molecules. The derivative of tumor accumulation versus time is the rate of extravasation. Based on the pharmacokinetics of Doxil and taking $k_{pr}/k_{el} = 10^{-3}$, the accumulation rate for a 100 μm vessel segment is about 28 liposomes per second for the first hour after administration, independent of the magnitude of the back rate constant $k_b$ (Fig 4A). The accumulation rate remains relatively high, greater than 10 liposomes per second, for a day or more depending on the value of constant $k_b$. The high accumulation rate is due to the long circulation time of the liposomes which also minimizes the effect of intravasation back into circulation except at very large values of $k_b$.

In contrast, the rate of tumor accumulation of doxorubicin decreases rapidly from about $9 \times 10^6$ molecules per second to less than about $1 \times 10^6$ per second within 10 minutes (Fig 4B). This is due to the rapid uptake in normal tissue, which quickly reduces the concentration in circulation. If the rate constant for intravasation is small, then the accumulation rate in the tumor is about $0.4 \times 10^6$ molecules per second, a factor of 20 lower than the initial accumulation rate, up to about 10 hours. For both Doxil and doxorubicin, if the rate constant for intravasation is large, typically $k_b/k_{pr} > 100$, the accumulation rate eventually becomes negative indicating a net loss from the tumor. For a drug where the blood concentration remains high, the influence of $k_b$ on the accumulation rate is delayed until relatively long times after administration. However, for drugs with rapid absorption in normal tissue (i.e. large distribution volume), the intravasation rate constant $k_b$ can significantly reduce tumor accumulation.

Fig 3. The influence of the EPR effect on the rate of tumor uptake of doxorubicin for an administered dose of 100 mg (50 mg m$^{-2}$). (A) Pharmacokinetics for doxorubicin. Symbols are data from a clinical trial reported by Gabizon et al. [12]. The solid red line is obtained from our model using values for $k_p$, $k_d$, and $k_d$ derived from median values of $A$, $B$, $\alpha$, and $\beta$ reported by Gabizon et al. [12] (Table 1), where $k_d = k_{10}$ when $k_{ad} \gg k_{pr}$. The dotted lines represents the pharmacokinetics for the minimum and maximum values of $A$, $B$, $\alpha$, and $\beta$. (B) Simulations of the pharmacokinetics for doxorubicin with $k_{pr}/k_{el} = 0$, $10^{-1}$, $10^{-2}$, and $10^{-3}$, and $k_b = 0$. (C) Amount of doxorubicin in tumor for $k_{pr}/k_{el} = 10^{-1}$, $10^{-2}$, $10^{-3}$, and $10^{-4}$, and $k_b = 0$. (D) Amount of doxorubicin in tumor for $k_{pr}/k_{el} = 10^{-1}$ and $k_d/k_{pr} = 0, 10, 100, 1000$. doi:10.1371/journal.pone.0123461.g003
Discussion

Implications of the model

The EPR effect plays an important role in modulating uptake of a drug to a solid tumor, and yet surprisingly little is known about the kinetics of tumor uptake. Developing a quantitative framework to describe the EPR effect is crucial to guide the design of drug delivery systems and ultimately in providing input in dosing and clinical management. Here we present a model to provide quantitative analysis of the EPR effect that uses pharmacokinetic measurements of the time dependent blood concentration as an input parameter. The rate constants $k_{epr}$ and $k_b$ describe extravasation to the tumor site and intravasation back into circulation, respectively. The amount of drug extravasating from the vascular system at a tumor site is dependent on the competition between the EPR effect and elimination due to the kidneys, MPS, and other non-tumor pathways. For drugs such as Doxil with a long elimination half-time, tumor accumulation increases rapidly. In contrast, tumor accumulation is significantly lower for drugs with very short elimination half-times, such as Doxorubicin, for the same value of $k_{epr}$. Intravasation from the tumor site back into circulation is an important and often ignored factor in determining tumor accumulation. As the rate constant for intravasation $k_b$ increases, loss of drug from the tumor to circulation becomes significant.

The model presented here provides quantitative insight into the EPR effect and the coupling between pharmacokinetics and tumor accumulation that will be useful for basic science and preclinical trials of new drugs and nanomedicines. Preclinical trials that quantify both pharmacokinetics and tumor accumulation (% ID) can be used to predict $k_{epr}$ values (Figs 2C and 3C). For example, we limited $k_{epr}/k_{el}$ to achieve tumor accumulations that are consistent with those reported in vivo in a mouse model, ranging from 0.01–10% and 0.001–1% ID for Doxil and doxorubicin respectively [15, 22, 23]; free doxorubicin reaches maximum accumulation faster in tumors but remains at concentrations roughly 10 times less than liposomal formulations due to differences in pharmacokinetics and uptake mechanisms [12, 23, 24]. Furthermore, this model can be used to predict how changes in nanomedicine design that modulate pharmacokinetics will influence tumor accumulation by modulating $k_{el}, k_{epr}$, and $k_b$.

This model also raises a number of key scientific questions concerning the rate constants $k_{epr}$ and $k_b$. Importantly, the model provides a quantitative framework to discuss these questions. (1) What is the spatial variability in tumor leakiness? (2) What is the variability in
leakiness from patient-to-patient within a tumor type? (3) What is the variability in leakiness across different tumor types?

There are two sources of spatial variability in tumor leakiness and tumor uptake: (1) intrinsic variations in leakiness per unit length of vessel, and (2) regional variations in vascular density. Non-uniform extravasation and discontinuous pooling of pegylated liposomes in a xenograft mouse model [6, 25] suggest spatial variations in $k_{ep}$. Vascular leakiness is expected to be greater at angiogenic sprouts compared to developed neovasculature. The accumulation of radiolabeled stealth liposomes was found to be about 10 times greater in the periphery compared to the necrotic core 24 hours after administration in a mouse tumor xenograft [26]; this is likely due to a higher vascular density at the tumor periphery and the increased interstitial pressure at the tumor core [27–29]. These results suggest that spatial variations in accumulation of an order of magnitude are reflected in $k_{ep}$ (Fig 2C). While in our model, there is a single tumor compartment and rate constant for extravasation, $k_{ep}$ (Fig 1E), additional tumor compartments and rate constants accounting for spatial variation (e.g. tumor core, periphery, interstitial pressure) may be introduced. Knowledge of the variation of $k_{ep}$ within a tumor may be used to determine a range of doses that distributes a therapeutically effective concentration of drug to all regions of the tumor.

The rate constants $k_{ep}$ and $k_b$ have units of $s^{-1}$ and are dependent on the length and leakiness of the tumor vasculature and hence are expected to be dependent on tumor type and exhibit patient-to-patient variations. Normalizing the rate constants to unit volume would allow comparison of different tumor sizes. Tumor accumulation of radiolabeled liposomes in a clinical study of patients with various tumor types ranged from 0.3 to 3.6% of the initial dose (ID) 72 hours post injection. When normalized by tumor weight (% ID/kg), uptake into breast tumors was roughly 3 times lower than lung tumors and 6 times lower than squamous cell cancer of the head and neck [22]. These patient-to-patient variations may be attributed to differences in density, structure, and inflammation of the tumor vasculature affecting blood flow and drug accumulation. The quantification of both drug accumulation and tumor perfusion will improve our understanding of the influence of tumor blood flow and vascularity on the EPR effect.

Measurement of the rate constants for extravasation and transport back into circulation ($k_{ep}$ and $k_b$) for different tumor types and assessment of patient-to-patient variations may improve dosing and clinical management. This requires detailed time-dependent measurements of both the pharmacokinetics and tumor accumulation, but these data do not exist for human clinical trials and are without sufficient granularity from preclinical studies in animal models. However, in vivo techniques, such as PET imaging of tumor accumulation of a labeled surrogate (e.g. radiolabeled pegylated liposomes) [22], may provide the temporal resolution needed to determine $k_{ep}$ and $k_b$ for individual patients. Similarly, these rate constants can be extracted from preclinical trials in animal models that measure drug accumulation as % ID in tumor homogenates at frequent time points. The ratio of $k_b/k_{ep}$ can provide a prognostic value of tumor response, since it captures both the rate of accumulation and clearance of the drug, which have been correlated with tumor regression [27]. Therapeutic efficacy and dosing intervals can be predicted and optimized from these rates constants.

Conclusions

This model represents a first step in quantitative analysis of tumor accumulation of a drug or nanomedicine by the EPR effect. There are models for almost every other step in drug delivery for cancer therapy (e.g. pharmacokinetics, diffusion, uptake, tumor growth, survival rates, etc.), but not the crucial EPR effect. Using pharmacokinetic data for Doxil and doxorubicin we show how the EPR effect influences tumor accumulation for different values of the rate constants for...
tumor uptake by the EPR effect and intravasation back into circulation. Modeling results show the kinetics of drug accumulation with time. By taking into account intravasation back into circulation, tumor uptake shows a characteristic maximum, with loss of drug from the tumor at longer times. This model provides a quantitative framework to guide preclinical trials of new chemotherapeutic delivery vehicles and ultimately to develop design rules that can increase targeting efficiency and decrease unwanted side effects in normal tissue.

Supporting Information

S1 File. Supplementary information. (1) Pharmacokinetic Model. (2) Relationship between $k_{10}$ and $k_{el}$. (3) Obtaining rate constants $k_{10}$, $k_{12}$, $k_{21}$ from pharmacokinetic data for Doxil and doxorubicin. (4) Simulations. (5) Derivation of the relationship between the pharmacokinetic parameters $A$, $B$, $\alpha$, and $\beta$ and the rate constants $k_{10}$, $k_{12}$, and $k_{21}$.

S2 File. Matlab simulation code.

S1 Table. The architecture of tumor vasculature.

Acknowledgments

The authors gratefully acknowledge support from NIH (U54CA151838 and R01CA170629).

Author Contributions

Conceived and designed the experiments: MY ADW MBU PCS. Performed the experiments: MY ADW. Analyzed the data: MY ADW PCS. Wrote the paper: ADW PCS.

References

1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583–92. doi: 10.1038/nrc1893 PMID: 16862189.
2. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced drug delivery reviews. 2011; 63(3):136–51. doi: 10.1016/j.addr.2010.04.009 PMID: 20441782.
3. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. Journal of controlled release: official journal of the Controlled Release Society. 2012; 164(2):138–44. doi: 10.1016/j.jconrel.2012.04.038 PMID: 22595146.
4. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. P Natl Acad Sci USA. 1998; 95(8):4607–12. doi: 10.1073/Pnas.95.8.4607 PubMed WOS:000073120800097. PMID: 9539785

5. Jain RK. Determinants of Tumor Blood-Flow—A Review. Cancer research. 1988; 48(10):2641–58. PubMed ISI:A1988N269700003. PMID: 3282647

6. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995; 55(17):3752–6. Epub 1995/09/01. PMID: 7641188.

7. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007; 2(12):751–60. doi: 10.1038/nnano.2007.387 PubMed ISI:000251456500010. PMID: 18654426

8. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012; 338(6109):903–10. doi: 10.1126/science.1226338 PMID: 23161990; PubMed Central PMCID: PMC3660151.

9. Gibaldi M, Perrier D. Pharmacokinetics. 3rd ed. 978–0824702953 I-, editor. New York: Dekker; 2006.
10. Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. Journal of controlled release: official journal of the Controlled Release Society. 2014; 187:133–44. doi: 10.1016/j.jconrel.2014.05.036 PMID: 24874289.

11. Barenholz Y. Doxil(R)—the first FDA-approved nano-drug: lessons learned. Journal of controlled release: official journal of the Controlled Release Society. 2012; 160(2):117–34. doi: 10.1016/j.jconrel.2012.03.020 PMID: 22484195.

12. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994; 54(4):987–92. PMID: 8313389.

13. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clinical pharmacokinetics. 2003; 42(5):419–36. doi: 10.2165/00003088-200342050-00002 PMID: 12739982.

14. Cameron JR, Skofronick JG, Grant RM, Cameron JR. Physics of the body. 2nd ed. Madison, Wis.: Medical Physics Pub.; 1999. xv, 394 p. p.

15. Dawidczyk CM, Russell LM, Searson PC. Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Frontiers in chemistry. 2014; 2:69. Epub 2014/09/10. doi: 10.3389/fchem.2014.00069 PMID: 25202889; PubMed Central PMCID: PMC4142601.

16. Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, Yang HS, et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clinical Cancer Research. 2006; 12(10):3193–9. doi: 10.1158/1078-0432.Ccr-05-0343 PMID: 16707620.

17. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clinical pharmacology and therapeutics. 1993; 53(5):555–61. PMID: 8387903.

18. Jacquet JM, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, et al. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer chemotherapy and pharmacology. 1990; 27(3):219–25. PMID: 2265458.

19. Erttmann R, Erb N, Steinhoff A, Landbeck G. Pharmacokinetics of doxorubicin in man: dose and schedule dependence. Journal of cancer research and clinical oncolgy. 1988; 114(5):509–13. PMID: 3182911.

20. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. Journal of pharmaceutical sciences. 2002; 91(6):1488–501. doi: 10.1002/jps.10161 PMID: 12115848.

21. Hilmas DE, Gillette EL. Morphometric analyses of the microvasculature of tumors during growth and after x-irradiation. Cancer. 1974; 33(1):103–10. Epub 1974/01/01. PMID: 4810083.

22. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7(2):243–54. Epub 2001/03/10. PMID: 11234875.

23. Laginha KM, Vervoort S, Charrois GJ, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(19 Pt 1):6944–9. Epub 2005/10/06. doi: 10.1158/1078-0432.Ccr-05-2365 PubMed WOS:000237685800034. PMID:16707620.

24. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17(11):3512–21. Epub 1999/11/05. PMID: 10550149.
28. Stapleton S, Milosevic M, Allen C, Zheng J, Dunne M, Yeung I, et al. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PloS one. 2013; 8(12): e81157. Epub 2013/12/07. doi: 10.1371/journal.pone.0081157 PMID: 24312530; PubMed Central PMCID: PMC3846845.

29. Folarin AA, Konerdin MA, Timonen J, Nagl S, Pedley RB. Three-dimensional analysis of tumour vascular corrosion casts using stereomaging and micro-computed tomography. Microvascular research. 2010; 80(1):89–98. Epub 2010/03/23. doi: 10.1016/j.mvr.2010.03.007 PMID: 20303995.